Agios Pharmaceuticals discontinued its Phase 2 trial of tebapivat for sickle cell disease after the drug failed to improve outcomes versus currently available therapies. The setback reduces near-term clinical upside for AGIO and is likely to weigh on sentiment around the program’s commercial potential.
Agios Pharmaceuticals discontinued its Phase 2 trial of tebapivat for sickle cell disease after the drug failed to improve outcomes versus currently available therapies. The setback reduces near-term clinical upside for AGIO and is likely to weigh on sentiment around the program’s commercial potential.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
